By Jonathan Stempel (Reuters) -Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback